Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03418363 · ClinicalTrials.gov registry record · Phase 4
How DHEA Supplements Affect Coagulation in Women Using Birth Control Pills
A Phase 4 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT03418363 is a Phase 4 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 15 participants.
The verdict
NCT03418363, a Phase 4 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
A randomized study is to learn more about how a supplement called DHEA (dehydroepiandrosterone) affects clotting factors in women taking combined oral contraceptive pills. Current research suggests that the progestin hormone in a specific type of birth control pill may increase a woman's blood clot risk. However, it is unknown exactly how the progestin causes the increased risk. This study aims to learn if taking a daily dose of supplemental androgen (dehydroepiandrosterone, or DHEA) in addition to birth control pills containing DRSP affects proteins related to coagulation.
Interventions
- DIETARY_SUPPLEMENT DHEA Oral Capsule
- OTHER Placebo Oral Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2018-01-16 |
| Est. Completion | 2019-12-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03418363
The ClinicalTrials.gov registry entry for NCT03418363 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which DHEA Oral Capsule is the first listed.
NCT03418363 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03418363 about?
NCT03418363 is a clinical study titled "How DHEA Supplements Affect Coagulation in Women Using Birth Control Pills". A randomized study is to learn more about how a supplement called DHEA (dehydroepiandrosterone) affects clotting factors in women taking combined oral contraceptive pills. Current research suggests that the progestin hormone in a specific type of birth control pill may increase a woman's blood clot ...
What is the current status of trial NCT03418363?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2018-01-16. Estimated completion is 2019-12-11.
What interventions are being tested in trial NCT03418363?
The interventions under investigation include: DHEA Oral Capsule (DIETARY_SUPPLEMENT), Placebo Oral Capsule (OTHER).
Who is sponsoring clinical trial NCT03418363?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.